Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors

NCT ID: NCT04990739

Last Updated: 2021-12-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-30
• Study Completion Date: 2024-01-31

Brief Summary

MetaboMed is developing MTB-9655, an orally bioavailable, first-in-class small molecule inhibitor of the human Acetyl coenzyme A (Acyl-CoA) synthetase short chain family member 2 (ACSS2) enzyme, as a potential treatment for patients with cancer.

This study is a Phase 1,First-in-Human (FIH), open-label dose-escalation study of MTB-9655 given daily as a single oral (PO) agent. Up to 30 patients with locally advanced, unresectable and/or metastatic solid tumor(s) are expected to be enrolled in the dose-escalation portion (Part A). The study will be conducted at 1 to 2 sites in the United States and Israel.

Detailed Description

This Phase 1 First-in-Human (FIH) study is to initiate clinical development of MTB-9655 in patients with advanced solid tumors who have failed or refused standard treatment, or who have a tumor for which no therapy of proven efficacy exists. This study of MTB-9655 may consist of 2 parts: a dose-escalation part to establish a safe and tolerable dose of MTB-9655 in patients with advanced or metastatic solid tumors for which no standard therapy is available or standard therapy has failed (Part A), and a dose expansion phase (Part B) which may be initiated at the Sponsor's discretion after the maximum tolerated dose (MTD) (or recommended Phase 2 dose [RP2D]) has been determined in the dose-escalation (Part A), and with approval of an amendment to the protocol. This study will be the basis for future studies. The study will identify the safety and tolerability of MTB-9655 when administered on a continuous dosing schedule (given by mouth on a 21-day schedule).

Conditions

Advanced Solid Tumor

Keywords

metastatic; ACSS2 inhibitor

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part A Dose-Escalation and Part B RP2D Dose-Expansion

Study has two parts:

1. Part A Dose-Escalation will evaluate MTB-9655 monotherapy administered in 21 days cycle,and will be conducted in 2 stages (accelerated titration and dose-escalation).

The first stage will consist of accelerated titration in single-patient cohorts for the initial two dose levels.

In the second stage, a conventional 3+3 schema using a modified Fibonacci dose titration strategy will be implemented. The first dose at every dose level and in every patient will be administered under close medical supervision, and the patients will be hospitalized for approximately 24 hours.

Up to 30 participants will participate in this dose escalation arm.

2. Part B dose-expansion will further explore the safety, PK and preliminary efficacy of MTB-9655 at the RP2D. The RP2D level will be no higher than the MTD identified in Part A.

Group Type: EXPERIMENTAL

MTB-9655

Intervention Type: DRUG

MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.

Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime.

Interventions

MTB-9655

MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.

Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Signed written informed consent.

2. Patient is at least 18 years-of-age at the time of signature of the informed consent form (ICF).

3. Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

4. Patient must have a confirmed diagnosis of locally advanced, unresectable and/or metastatic solid tumor(s), have failed standard treatment, or refuse standard treatment, or have a tumor for which no therapy of proven efficacy exists, or a tumor that is not amenable to standard therapies.

5. Patient has measurable disease on imaging based or non-measurable disease.

6. Patient will be requested to provide a fresh pre-treatment biopsy specimen, otherwise they are required to provide an archival diagnostic tumor sample that is <1 year old.

7. Patient has a life expectancy ≥3 months according to the Investigator's judgment.

8. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at screening within 72 hours of first dose of MTB-9655. In addition, WOCBP are required to use two forms of acceptable contraception.

9. Male patients with WOCBP partners must agree to use highly effective contraceptive measures throughout the study starting with screening visit through 120 days after the last dose.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:

1. Treatment with any of the following:

• Any systemic anti-cancer chemotherapy, small molecule, biologic, or hormonal agent from a previous treatment regimen or clinical study within 28 days or 5 half-lives (whichever is shorter) prior to the first dose of study drug. At least 10 days must have elapsed between the last dose of such agent and the first dose of study drug.
• Wide-field radiotherapy administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting study drug.
• Major surgery(excluding placement of vascular access) within 3 weeks of first dose of study drug.
• Prior treatment with other drug with the same mechanism of action (directed to ACSS2).
• Receiving systemic corticosteroid therapy 1 week prior to the first dose of study drug or receiving any other form of systemic immunosuppressive medication for medically significant acute or chronic conditions.

2. Persistent toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade >1 severity that is related to prior therapy.

3. Central nervous system tumor, metastasis(es), and/or carcinomatous meningitis identified either on the baseline brain imaging obtained during the screening period or identified prior to consent.

4. Active infection requiring treatment.

5. Out-of-range laboratory values defined as:

• Absolute neutrophil count (ANC) <1.5 × 10^9/L
• Hemoglobin <9 g/dL
• Platelets <100 × 10^9/L)
• Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) >2.5 × the upper limit of normal (ULN) or ≥5 × ULN with liver involvement
• Total bilirubin >1.5 × ULN
• Serum creatinine >1.5 × ULN or creatinine clearance (CrCl≤60mL/min, measured or calculated using the Cockcroft-Gault Method
• International Normalized Ratio (INR) or prothrombin time (PT) >1.5 × ULN and activated partial thromboplastin time (aPTT) >1.5 × ULN (unless patient is receiving anticoagulant therapy)

6. Inability to swallow oral medications or presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of MTB-9655 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea Grade ≥2, malabsorption syndrome).

7. Any of the following cardiac criteria:

• Known history of marked prolongation of QT/corrected QT(QT/QTc) interval.
• Clinically significant cardiovascular disease, including cerebral vascular accident/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure,or serious uncontrolled cardiac arrhythmia requiring medication.
• History of additional risk factors for Torsade de Pointes (including heart failure, hypokalemia, family history of long QT syndrome, and use of concomitant medications that prolong the QT/QTc interval.
• Patients with a left ventricular ejection fraction (LVEF) <50%.

8. History of concomitant malignancy with recurrence <3 year from enrolment.

9. Expected to require any other form of systemic or localized antineoplastic therapy while on trial.

10. Significant liver cirrhosis defined as Child-Pugh Class B or C.

11. History of hemolytic disorders.

12. Active infection with human immunodeficiency virus (HIV).

13. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.

14. Pregnant or breastfeeding.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MetaboMed Inc

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Meredith McKean, MD

Role: STUDY_CHAIR

SCRI Development Innovations, LLC

Locations

Tennessee Oncology

Nashville, Tennessee, United States

Site Status: RECRUITING

Rambam MC

Haifa, , Israel

Site Status: RECRUITING

Sourasky MC

Tel Aviv, , Israel

Site Status: RECRUITING

Countries

United States; Israel

Central Contacts

Sarah Cannon Development Innovations

Role: CONTACT

Phone: 844-710-6157

Email: CANN.InnovationsMedical@sarahcannon.com

Hagop Youssoufian, MD

Role: CONTACT

Email: Hagop.Youssoufian@metabomed.com

Facility Contacts

Meredith McKean, MD

Role: primary

Haley Saunders, BS

Role: backup

Ruth Perets, MD

Role: primary

Ravit Geva, MD

Role: primary

Other Identifiers

MTB-9655-101

Identifier Type: -

Identifier Source: org_study_id